Determination of the phosphorylated metabolites of gemcitabine and of difluorodeoxyuridine by LCMSMS

Nucleosides, Nucleotides and Nucleic Acids

Volumn 30, Issue 12, 2011, Pages 1203-1213

  Honeywell, Richard J ^a   Giovannetti, Elisa ^a   Peters, G J ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Mechanism of action studies; Nucleoside conformation; Physical properties

Indexed keywords

ALKALINE PHOSPHATASE; DIFLUORODEOXYURIDINE; DRUG METABOLITE; GEMCITABINE; NUCLEOSIDE; NUCLEOTIDE; UNCLASSIFIED DRUG;

ARTICLE; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHOSPHORYLATION; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; CYTOSOL; DEOXYCYTIDINE; FLOXURIDINE; HUMANS; MASS SPECTROMETRY; NUCLEOTIDES; PHOSPHORYLATION;

EID: 84855868841     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770.2011.632389     Document Type: Article

References (28)

1. Bergman, A. M.; Pinedo, H. M.; Peters, G. J. Determinants of resistance to 2', 2'-difluorodeoxycytidine (gemcitabine). Drug Resist Updat. 2002, 5, 19-33.
2. Huang, P.; Chubb, S.; Hertel, L. W.; Grindey, G. B.; Plunkett, W. Action of 2', 2'-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991, 51, 6110-6117.
3. Cardenes, H. R.; Chiorean, E. G.; Dewitt, J.; Schmidt, M.; Loehrer, P. Locally advanced pancreatic cancer: current therapeutic approach. Oncologist 2006, 11, 612-623. (Pubitemid 43967616)
4. Kroep, J. R.; Peters, G. J.; Nagourney, R. A. Clinical activity of gemcitabine as a single agent and in combination, in Deoxynucleoside Analogs in Cancer Therapy, ed. G. J. Peters, Humana Press, 2007, pp. 253-288.
5. Kose, M. F.; Meydanli, M. M.; Tulunay, G. Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma. Expert Rev. Anticancer Ther. 2006, 6, 437-443. (Pubitemid 44192925)
6. von der Maase, H.; Hansen, S. W.; Roberts, J. T.; Dogliotti, L.; Oliver, T.; Moore, M. J.; et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 2000, 18, 3068-3077.
7. Heinemann, V.; Hertel, L. W.; Grindey, G. B.; Plunkett, W. Comparison of the cellular pharmacokinetics and toxicity of 2', 2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1988, 48, 4024-4031.
8. De Lange, S. M.; Van der Born, K.; Kroep, J. R.; Jensen, H. A.; Pfeiffer, P.; Cleverly, A.; et al. No evidence of gemcitabine accumulation during weekly administration. Eur. J. Clin. Pharmacol 2005, 61, 843-849. (Pubitemid 41720273)
9. de Lange, S. M.; Van Groeningen, C. J.; Kroep, J. R.; Van Bochove, A.; Snijders, J. F.; Peters, G. J.; et al. Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer. Ann. Oncol. 2004, 15, 484-488. (Pubitemid 38444554)
10. Peters, G. J.; Clavel, M.; Noordhuis, P.; Geyssen, G. J.; Laan, A. C.; Guastalla, J.; et al. Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule. J. Chemother. 2007, 19, 212-221. (Pubitemid 46697743)
11. Veltkamp, S. A.; Pluim, D.; van Eijndhoven, M. A.; Bolijn, M. J.; Ong, F. H.; Govindarajan, R.; et al. New insights into the pharmacology and cytotoxicity of gemcitabine and 2', 2'-difluorodeoxyuridine. Mol. Cancer Ther. 2008, 7, 2415-2425.
12. Veltkamp, S. A.; Hillebrand, M. J.; Rosing, H.; Jansen, R. S.; Wickremsinhe, E. R.; Perkins, E. J.; et al. Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. J. Mass Spectrom. 2006, 41, 1633-1642. (Pubitemid 46045802)
13. Veltkamp, S. A.; Jansen, R. S.; Callies, S.; Pluim, D.; Visseren-Grul, C. M.; Rosing, H.; et al. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clin. Cancer Res. 2008, 14, 3477-3486.
14. Jansen, R. S.; Rosing, H.; Schellens, J. H.; Beijnen, J. H. Simultaneous quantification of 2',2'-difluorodeoxycytidine and 2', 2'-difluorodeoxyuridine nucleosides and nucleotides in white blood cells using porous graphitic carbon chromatography coupled with tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2009, 23, 3040-3050.
15. Sigmond, J.; Honeywell, R. J.; Postma, T. J.; Dirven, CM.; de Lange, S. M.; van der Born, K.; et al. Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer. Ann. Oncol. 2009, 20, 182-187.
16. Honeywell, R.; Laan, A. C.; van Groeningen, C. J.; Strocchi, E.; Ruiter, R.; Giaccone, G.; et al. The determination of gemcitabine and 2-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2006, 847, 142-152.
17. Song, L.; James, S. R.; Kazim, L.; Karpf, A. R. Specific method for the determination of genomic DNA methylation by liquid chromatography-electrospray ionization tandem mass spectrometry. Anal. Chem. 2005, 77, 504-510. (Pubitemid 40116829)
18. Zor, T.; Selinger, Z. Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. Anal. Biochem. 1996, 236, 302-308. (Pubitemid 26136110)
19. Shewach, D. S. Quantitation of deoxyribonucleoside 5'-triphosphates by a sequential boronate and anion-exchange high-pressure liquid chromatographic procedure. Anal. Biochem. 1992, 206, 178-182.
20. Dreyer, R.; Cadman, E. Use of periodate and methylamine for the quantitation of intracellular 5-fluoro-2-deoxyuridine-5'-monophosphate by high-performance liquid chromatography. J. Chromatogr. 1981, 219, 273-284. (Pubitemid 12140606)
21. Peters, G. J.; de Abreu, R. A.; Oosterhof, A.; Veerkamp, J. H. Concentration of nucleotides and deoxynucleotides in peripheral and phytohemagglutinin-stimulated mammalian lymphocytes. Effects of adenosine and deoxyadenosine. Biochim. Biophys. Acta 1983, 759, 7-15. (Pubitemid 13013115)
22. Smid, K.; Van Moorsel, C. J.; Noordhuis, P.; Voorn, D. A.; Peters, G. J. Interference of gemcitabine triphosphate with the measurements of deoxynucleotides using an optimized DNA polymerase elongation assay. Int. J. Oncol. 2001, 19, 157-162.
23. Ruiz Van Haperen, V.; Veerman, G.; Boven, E.; Noordhuis, P.; Vermorken, J. B.; Peters, G. J. Schedule dependence of sensitivity to 2', 2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem. Pharmacol. 1994, 48, 1327-1339.
24. Adema, A. D.; Losekoot, N.; Smid, K.; Kathmann, I.; Myhren, F.; Sandvold, M. L.; et al. Induction of resistance to the lipophilic cytarabine prodrug elacytarabine (CP-4055) in CEM leukemic cells. Nucleosides Nucleotides Nucleic Acids 2010, 29, 394-399.
25. Kichenin, K.; Pignede, G.; Fudalej, F.; Seman, M. CD3 activation induces concentrative nucleoside transport in human T lymphocytes. Eur. J. Immunol. 2000, 30, 366-370. (Pubitemid 30098828)
26. Bijnsdorp, I. V.; Schwendener, R. A.; Schott, H.; Fichtner, I.; Smid, K.; Laan, A. C.; et al. Cellular pharmacology of multi-and duplex drugs consisting of ethynylcytidine and 5-fluoro-2'-deoxyuridine. Invest. New Drugs 2011, 29, 248-257.
27. Van Moorsel, C. J.; Smid, K.; Voorn, D. A.; Bergman, A. M.; Pinedo, H. M.; Peters, G. J. Effect of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines. Int. J. Oncol. 2003, 22, 201-207.
28. Zhang, W.; Tan, S.; Paintsil, E.; Dutschman, G. E.; Gullen, E. A.; Chu, E.; et al. Analysis of deoxyribonucleotide pools in human cancer cell lines using a liquid chromatography coupled with tandem mass spectrometry technique. Biochem. Pharmacol. 2011, 82, 411-417.